Medistim (MEDI) Q4 2024 earnings summary

Executive summary

• Achieved record Q4 2024 sales of NOK 151.1 million, up 11.4% year-over-year, and full-year revenue of NOK 562.6 million, up 6.9%, with strong growth in Americas and EMEA offset by APAC decline.

• EBIT for Q4 was NOK 25.8 million (up 16.1% YoY); full-year EBIT was NOK 131.1 million, stable year-over-year, with margin down to 23.3% due to higher investments.

• Board proposes a dividend of NOK 6 per share for 2024, reflecting strong cash flow and positive outlook.

• Launch of INTUI software and initiation of the PATENT clinical study in vascular surgery support future growth.

• Strengthened commercial team with new CCO and regional leadership to drive growth.

Financial highlights

• Q4 profit after tax rose to NOK 21.3 million, with full-year profit at NOK 103.8 million, both stable year-over-year.

• Gross margin improved by 3% in Q4; EBIT margin for the year declined from 25% to 23.3%.

• Earnings per share for the year remained at NOK 5.67.

• Cash position at year-end was NOK 179.2 million, up from NOK 153.8 million.

• Equity ratio at year-end was 74.85%.

Outlook and guidance

• Optimistic outlook for 2025, with growth expected from INTUI software, Vascular segment, and Americas.

• Commercial operations strengthened with new leadership and expanded direct market coverage.

• Continued investment in R&D, direct market expansion, and clinical studies to support growth.